about
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsOncogenes in cell survival and cell death.The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomasThe SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.From anecdote to targeted therapy: the curious case of thalidomide in multiple myelomaDevelopment of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ.BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.Plasmodium species co-infection as a cause of treatment failure.An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.High rates of potentially infectious exposures between immunocompromised patients and their companion animals: an unmet need for education.Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use.FISH detection of PML-RARA fusion in ins(15;17) acute promyelocytic leukaemia depends on probe size.CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.Carotid artery haemorrhage: an uncommon complication of constipation in a patient with severe haemophilia A.AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.Oxidative haemolysis due to 'poppers'.Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens.Streptococcus pneumoniae septicemia associated with red blood cell transfusion.Manipulation of B-cell responses with histone deacetylase inhibitors.Serum protein electrophoresis: a precautionary tale.The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts.The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.Inter-laboratory discordance of beta-2 microglobulin results: impact on the validity of the international staging system for multiple myeloma.Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.Letter to the Editor, "BET inhibitor JQ1 blocks inflammation and bone destruction".
P50
Q34048020-001C6726-BE20-4EE1-B71A-71CF99D5DE06Q34263870-A29E482C-53EB-4330-834F-810D7DEFC60EQ34658892-684459CD-3CF9-4769-AA7D-BE66E9BA1313Q36418000-B33D9C3E-5729-4C8D-A417-9B003C514B6DQ36541067-F33B103A-AA19-4B17-9E4C-640E0E368E7BQ36568780-952BD796-A47A-4DC2-8E18-C1725ADAF106Q36730752-63BB3078-6622-4A50-B468-0CE99446A08BQ36761564-903D915D-ABBE-41DF-99EC-9334D9420A59Q36846723-324A0DCF-8C9C-46C0-97F3-C07CE721F806Q37006778-8A0AA5C4-1DFE-4491-BE4B-510463FD715CQ37211962-CA2F2AAD-2532-4C6E-A76A-36F0838F90F5Q37690225-2B3563B3-B32C-43ED-9F6A-49825EFDAB63Q38074017-A8E45229-0486-446E-8EA9-30AC899DC58CQ38210393-A1C8F443-BA64-4160-87E2-90ADB40E162EQ38725208-AAD9B837-ECB9-4789-90D1-8CF8728DB378Q38750125-1E459CC0-07B6-49FE-845D-31540BCA9282Q38758468-EE6F70B0-3BE3-4CCD-BE54-3CC8670E3D71Q38791113-4BA02B0F-18D9-4D1E-B11F-D967EB244646Q38868849-DC115F62-396F-4AD6-B4EC-3DB0B55491DCQ39070833-E7388FFC-A584-4A09-A643-E147A9015C16Q39208340-D26CF6ED-6F5D-4BC0-AE4F-847C5EBD9313Q40307970-4C077837-8B31-4453-9C1A-2F27FC3DCC80Q41995006-6CD1BA3E-4D9E-45C7-9756-D00462E60314Q42078133-C47512EA-722F-475F-8497-7B0CFFC4B432Q42335354-B47696F3-B645-42F8-A54F-308B1F6A625DQ45862532-AE52575E-9813-4E41-B40A-1A707750CFDDQ45867044-F49F052C-2F06-43F4-B13F-9EF7C6D40D57Q45967652-3F83574A-7D9E-4452-80D3-B1027CBB4D96Q46598292-B2F50359-5AE8-4F26-963B-8D4DCFB86F6EQ46752273-DE57FF92-FD98-487E-860A-2071285F643AQ47555589-5E9CD6E0-1849-492D-8BAA-4DB80685863DQ50640609-C9BF9BE0-0598-4871-88F8-311BC13CC55DQ50738767-B07386A9-3436-44E9-BEA1-2A7DDDFDCA7BQ51139382-501026EA-7663-404D-9C26-B34C01D25007Q52899177-393D22A4-8023-46F4-BE31-D14683CCE296Q52966216-D4B2B0E3-4C61-435F-8343-5AB5C74A3BE1Q53052024-E93E1053-1794-4A18-8B45-EAC4E7A9CCD3Q53090671-93964239-0A1F-4D5A-9C94-59C01675BBF8Q53235785-4E55BA6A-66D1-4634-9C0F-63FC161E5829Q54722445-9E16F7AD-4096-42AE-AE53-F255E9316DF9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jake Shortt
@ast
Jake Shortt
@en
Jake Shortt
@es
Jake Shortt
@nl
Jake Shortt
@sl
type
label
Jake Shortt
@ast
Jake Shortt
@en
Jake Shortt
@es
Jake Shortt
@nl
Jake Shortt
@sl
prefLabel
Jake Shortt
@ast
Jake Shortt
@en
Jake Shortt
@es
Jake Shortt
@nl
Jake Shortt
@sl
P106
P1153
17136069200
P21
P31
P496
0000-0003-3185-6488